Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.

Authors :: Shore, Neal D.
Nishiyama, Hiroyuki
Shariat, Shahrokh F.
Steinberg, Gary
Kamat, Ashish M.
Alanee, Shaheen Riadh
Nam, Kijoeng
Imai, Kentaro
Kapadia, Ekta
Hahn, Noah M.
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS722-TPS722, 193p
Publication Year :: 2024

Full Text Access

Tools